GAG
NTLA icon

Goodman Advisory Group’s Intellia Therapeutics NTLA Stock Holding History

Goodman Advisory Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8
Closed -$57 – 181
2025
Q1 		$57 Buy
+8
New +$81 ﹤0.01% 180
2024
Q4 		– Sell
-8
Closed -$164 – 135
2024
Q3 		$164 Hold
8
– – ﹤0.01% 194
2024
Q2 		$179 Hold
8
– – ﹤0.01% 175
2024
Q1 		$220 Hold
8
– – ﹤0.01% 169
2023
Q4 		$244 Hold
8
– – ﹤0.01% 150
2023
Q3 		$253 Hold
8
– – ﹤0.01% 155
2023
Q2 		$326 Hold
8
– – ﹤0.01% 154
2023
Q1 		$298 Hold
8
– – ﹤0.01% 156
2022
Q4 		$0 Hold
8
– – ﹤0.01% 157
2022
Q3 		$0 Hold
8
– – ﹤0.01% 170
2022
Q2 		$0 Buy
+8
New +$406 ﹤0.01% 180

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goodman Advisory Group's NTLA Position: Q2 2025 in Review

Goodman Advisory Group sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 8 shares — an estimated $57 sold.

Goodman Advisory Group first reported a position in NTLA in Q2 2022 and held it in 11 quarters. The position peaked at $326 in Q2 2023. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Goodman Advisory Group reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Goodman Advisory Group sold 8 Intellia Therapeutics shares in Q2 2025, an estimated $57.
  • Goodman Advisory Group first reported a position in Intellia Therapeutics in Q2 2022 and held it in 11 quarters.
  • Goodman Advisory Group's Intellia Therapeutics position peaked at $326 in Q2 2023.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Goodman Advisory Group's 13F filing for Q2 2025, filed 18 Aug 2025.